<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663231</url>
  </required_header>
  <id_info>
    <org_study_id>69726</org_study_id>
    <nct_id>NCT03663231</nct_id>
  </id_info>
  <brief_title>Duration of Effect of Biotene Spray in Patients With Dry Mouth</brief_title>
  <official_title>Duration of Effect of Biotene Spray in Patients With Symptomatic Dry Mouth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the duration of effect of a single dose of Biotène Moisturizing Mouth Spray in
      subjects who complain of a clinically dry mouth. The effect of the product will be compared
      to a control spray (water).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean duration of action of intervention</measure>
    <time_frame>baseline up to 2 hours</time_frame>
    <description>Participant will receive a dose of Biotene and will be asked if their mouth is dry up to 2 hrs. The time at which their mouth becomes dry again will be the duration of action.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean subject evaluation of test reagent</measure>
    <time_frame>2 hours</time_frame>
    <description>Subjects will be given a 10 question survey that assesses their tolerability, acceptability, and ease of use of product. The range of the questionnaire score is 1-30 with 30 indicating better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Dry Mouth</condition>
  <arm_group>
    <arm_group_label>Biotene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People who present with dry mouth and will receive a single dose of Biotene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>People who present with dry mouth and will receive a single dose of an alternative agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biotene</intervention_name>
    <description>Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.</description>
    <arm_group_label>Biotene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IND/IDE exempt device primarily water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults who are in good general health and reply initially affirmatively to the
             question, &quot;Do you feel that your mouth is too dry and causes you discomfort at times
             during the day other than on awakening from sleep?&quot; This question is an adaptation of
             the question used successfully by Jose and others (2016) to recruit study subjects.

          -  Adults who are able to communicate easily in English and who are able to demonstrate
             understanding of the study instructions.

          -  Adults who are physically able to perform an unstimulated whole saliva flow rate
             (UWSFR) test and who produce 0.2 mL/min or less of saliva.

        Exclusion Criteria:

          -  Adults under the care of a health professional specifically for xerostomia treatment,
             including those taking prescription systemic parasympathetic medications.

          -  Adults who regularly &quot;self-medicate&quot; their xerostomia with water or other agents or
             products designed to treat their xerostomia and are unwilling or unable to cease use
             of the agent for at least 48 hours prior to the two test visits.

          -  Adults who are primarily mouth breathers (i.e. mouth breathing secondary to nasal
             obstruction)

          -  Adults who cannot consent for themselves or have physical/mental disabilities
             requiring a caregiver.

          -  Adults with a known allergy to any of the ingredients in Biotène Spray (eg. dairy
             allergy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester Eastman Dental Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Ralph Saunders</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

